ArticleInfection and drug resistance2019
Outcomes of therapeutic keratoplasty for severe infectious keratitis in Chongqing, a 16-year experience.
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Therapeutic penetrating keratoplasty for recalcitrant microbial keratitis: An update.World journal of transplantation · 2026Review
- Article
- Current Challenges and Long-Term Outcomes in Corneal Transplantation in Infectious Keratitis-A Systematic Review.Journal of clinical medicine · 2026Review
- A complex case of Nocardia keratitis: challenges in diagnosis and therapy.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- New Frontiers inBiology · 2023Review
- A Pilot Study to Evaluate Genipin inInternational journal of molecular sciences · 2023Article
- Two-step strategy-conjunctival flap covering surgery combined with secondary deep anterior lamellar keratoplasty for the treatment of high-risk fungal keratitis.International journal of ophthalmology · 2023Article
- Management of Filamentous Fungal Keratitis: A Pragmatic Approach.Journal of fungi (Basel, Switzerland) · 2022Review
- Genipin in an Ex Vivo Corneal Model of Bacterial and Fungal Keratitis.Translational vision science & technology · 2021Article
- Post-keratoplasty Infectious Keratitis: Epidemiology, Risk Factors, Management, and Outcomes.Frontiers in medicine · 2021Review
- Incidence of and Risk Factors for Postoperative Hyphema After 23-Gauge Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the outcomes of therapeutic keratoplasty for severe infectious keratitis in Chongqing (Southwest China). PATIENTS AND
methodsThe records of 561 eyes that underwent therapeutic keratoplasty for refractory microbial keratitis from 2001 to 2016 were analyzed in this retrospective study. Data included demographic information, microbiological investigations, associated factors, graft size, preoperative status, postoperative complications, and final anatomical outcomes.
resultsTrauma was the most common cause (267, 47.6%) for corneal ulcers leading to therapeutic keratoplasty. The etiological diagnosis included bacterial keratitis (80 eyes, 14.3%), fungal keratitis (317 eyes, 56.5%), acanthamoeba keratitis (3 eyes, 0.5%), and mixed bacteria/fungal infection (15 eyes, 2.7%). Anatomical success was achieved for 492 eyes (87.7%), with bacterial keratitis having a better outcome than fungal and mixed infections. Diabetes and preoperative time ≥30 days were significantly associated with anatomical failure in the multivariate logistic regression (
conclusionTherapeutic keratoplasty was an effective procedure in managing refractory infectious keratitis. Prompt and appropriate surgery would result in fewer complications and better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.